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Clarity about the nitric oxide (NO) concentrations existing physiologically is essential for developing a
quantitative understanding of NO signalling, for performing experiments with NO that emulate reality,
and for knowing whether or not NO concentrations become abnormal in disease states. A decade ago,
a value of about 1 lM seemed reasonable based on early electrode measurements and a provisional esti-
mate of the potency of NO for its guanylyl cyclase-coupled receptors, which mediate physiological NO
signal transduction. Since then, numerous efforts to measure NO concentrations directly using electrodes
in cells and tissues have yielded an irreconcilably large spread of values. In compensation, data from sev-
eral alternative approaches have now converged to provide a more coherent picture. These approaches
include the quantitative analysis of NO-activated guanylyl cyclase, computer modelling based on the
type, activity and amount of NO synthase enzyme contained in cells, the use of novel biosensors to mon-
itor NO release from single endothelial cells and neurones, and the use of guanylyl cyclase as an endog-
enous NO biosensor in tissue subjected to a variety of challenges. All these independent lines of evidence
suggest the physiological NO concentration range to be 100 pM (or below) up to 5 nM, orders of mag-
nitude lower than was once thought.
 2009 Elsevier Inc. All rights reserved.Introduction
It is more than 20 years since nitric oxide (NO) emerged as a
biological signalling molecule, initially in the cardiovascular, ner-
vous and immune systems [1–4] and then almost everywhere else
as well [5]. Were it a conventional type of hormone or transmitter,
its principal modes of operation should be well understood by
now. For example, over a similar time frame, the amino acid gluta-
mate progressed from being simply a putative neurotransmitter in
the central nervous system to being recognized as the major excit-
atory neurotransmitter therein [6] with complex primary actions
in synapses that can now be accurately simulated in sub-microm-
eter dimensions and on a sub-millisecond time scale [7]. With NO,
achieving this degree of clarity still seems a rather distant
prospect.
The mechanisms of NO formation by the three NO synthase en-
zymes (neuronal, endothelial and inducible, or nNOS, eNOS and
iNOS) have become quite well established and their functioning
in a cell-free environment can be modelled with a good degree of
accuracy [8]. Beyond that there lacks a coherent empirical or con-
ceptual framework for how NO operates physiologically. One
drawback is that the lack of chemical specialization of the NO mol-ll rights reserved.
hwaite).ecule renders fairly hopeless any attempt to exploit agonist/antag-
onist-based pharmacology that has traditionally been so proﬁtable.
Moreover, a molecule with the physicochemical properties of NO
had not been encountered previously in the ﬁeld of biological sig-
nalling, necessitating the formulation of a somewhat different set
of rules for how it works. Most obviously, NO diffuses freely and
very rapidly in three-dimensions away from its point of synthesis
rather than being spatially constrained in the intracellular or extra-
cellular environment by membranes. How far does it spread in bio-
logically relevant concentrations? What is the proﬁle of NO release
over time from the different sources? How is it captured to elicit
biological responses? The answers to these key questions remain
matters of speculation and debate. Moreover, depending on its
concentration and/or the period of exposure, NO may exert multi-
ple effects ranging from activation of its guanylyl cyclase (GC)-cou-
pled receptor proteins, through to inhibition of cellular respiration
by binding to cytochrome c oxidase in mitochondria, through to
participation in various chemical reactions.
Where physiology begins and ends within this spectrum of po-
tential activities is probably the most important question in the
ﬁeld as a whole, and remains the source of much uncertainty
and, perhaps also, wishful thinking. Judging from the literature, al-
most anything from femtomolar [9] up to hundreds of micromolar
[10] concentrations can be regarded as physiological. The lack of
consensus means that there are few constraints on the amounts
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Fig. 2. Comparative concentration–response curves for NO or nitrosoglutathione
(GSNO) for the stimulation of GC activity and for eliciting downstream effects. (A)
Clamped NO concentrations were delivered to intact rat platelets maintained
in vitro (ﬁlled squares) or to puriﬁed bovine lung GC incubated with presumed
physiological concentrations of GTP and ATP (circles); the resulting GC activity is
expressed as a fraction of maximum (left-hand ordinate). The concentration–
response curve for cGMP-dependent phosphorylation of vasodilator-activated
phosphoprotein (VASP) after exposing rat platelets to NO for 1 min is also
expressed as a fraction of the maximum level achieved (open squares and right-
hand ordinate). Data are from Roy et al. [47] and Mo et al. [48]. (B) Comparative
potency of S-nitrosoglutathione for elevating cGMP (1 min exposure) and eliciting
relaxation of rat aorta in vitro; from Mullershausen et al. [54] with permission.
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criminate results that have physiological or pathological signiﬁ-
cance from those that are biologically meaningless. Clarity about
this issue is vital for the development of a quantitative understand-
ing of the principles of NO signaling, for designing experiments
using exogenous or endogenous sources of NO that emulate reality,
and for knowing if and when NO concentrations become abnormal.
Here we scrutinise the evidence and arrive at some broad conclu-
sions. Physiological NO concentrations are taken to be those that
are not, generally speaking, injurious and which are found during
normal tissue functioning, although reference to pathological situ-
ations is also included.
Attempts at direct measurement
Direct electrochemical detection of NO has been used for many
years to try to measure the concentration of NO in cells and tissues,
both basally and in response to various stimulators of NO produc-
tion. Direct determination of NO concentrations would be expected
to provide the best solution but the results have been disappoint-
ing. One only need look at the huge variability in tissue NO concen-
trations reported by different groups using different electrodes to
appreciate the scale of the problem: the range covers 106 orders
of magnitude (Fig. 1 and Table 1). Even for a given tissue the vari-
ability is improbably large. In arteries, for example, NO concentra-
tions produced in vitro on application of acetylcholine have ranged
from 2.5 to 390 nM [11,12]. Similarly, ischaemia in rat brain in vivo
has been reported to raise NO by 17 nM or 1 lM [13,14].
One reason for such a wide spread of recorded endogenous NO
concentrations is likely to be cross-reactivity of some electrodes
with other biological species. Speciﬁcity of microelectrodes for
NO comes, in part, from the redox potential for NO oxidation but
as other biological species, for instance nitrite, dopamine, 5-
hydroxytryptamine (5-HT) and tyrosine are oxidised at similar
potentials, these species are common cross-reactants [15,16]. In
aiming to reduce interference, electrodes are coated with mem-
branes such as Naﬁon, which is impermeable to negatively charged
species such as nitrite, and o-phenylenediamine, which reduces
interference by cationic substances such as dopamine and 5-HT
[17]. The degree of selectivity depends on the number of coatings
of these membranes and their integrity [17,18], and day-to-day
electrode behaviour can change dramatically [19].
Many authors do not discuss the selectivity of their electrodes,
so interpretation of their records is problematic. Additionally, some
reported selectivity ratios would be insufﬁcient to discriminate be-
tween low levels of NO and physiological levels of potential interf-
erents. For example, Ferreira et al. report a selectivity ratio for NO
versus dopamine of 18:1, and versus ascorbate of 750:1 [20]. Brain
ascorbate concentrations are estimated to be 500 lM extracellu-R
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Fig. 1. NO concentrations reported for different tissues. Data are from Table 1.larly, however [21], and this level was found to increase by 250–
500 lM on application of NMDA and glutamate [22]. The electrode
used by Ferreira et al. would record such a change in ascorbate as
330–660 nM NO. Similarly, neuronal activity increased brain dopa-
mine levels to 500 nM [23], which would be recorded as an appar-
ent NO increase of 28 nM. Ferreira et al. report an increase in NO of
250–350 nM on application of NMDA and glutamate [20], a result
that could be accounted for by cross-reactivity with ascorbate and
dopamine.
Some studies have attempted to discriminate between NO and
interferents, reasoning that only the portion of the signal that is
sensitive to NOS inhibition represents NO (e.g. [24]). This approach
might also be misleading because the generation of NO and of po-
tential interferents may be interdependent. For example, NO has
been shown to regulate dopamine release [25] and to stimulate
ascorbate efﬂux from red blood cells [26]. Testing for interference
by physiological concentrations of these contaminants should re-
duce the possibility of artefact. It may be no coincidence that stud-
ies that explicitly report a lack of sensitivity to biologically relevant
concentrations of, among others, dopamine, ascorbate and 5-HT,
tend to report lower evoked NO concentrations (<10 nM [27–
30]). At the lower extreme, that the concentration could be in
the femtomolar range [9] seems improbable because no biological
effects of NO have been observed in this concentration range and
because the electrode design adopted, in the originator’s hands,
Table 1
Electrode measurements of NO concentrations in different tissues.
Preparation In vivo/vitro Stimulation [NO] (nM) Reference
Vasculature
Dog femoral artery In vitro Acetylcholine 2.5 [11]
Rat mesenteric artery In vitro Acetylcholine 20 [141]
Rabbit coronary artery In vitro Acetylcholine 295 [142]
Rat aorta In vitro Acetylcholine 390 [12]
Human radial and mammary artery In vitro Acetylcholine 15 (both) [143]
Human radial artery In vitro Bradykinin 6 [143]
Human mammary artery In vitro Bradykinin 20 [143]
Porcine pulmonary artery In vitro Bradykinin 160 [144]
Porcine pulmonary vein In vitro Bradykinin 103 [144]
Porcine aorta In vitro Bradykinin 450 [31]
Porcine aorta In vitro Bradykinin + indomethacin 105 [145]
Rabbit aorta In vitro Carbachol 17 [146]
Rabbit femoral artery In vivo Ischaemia 140 [147]
Rat mesenteric artery In vitro Noradrenaline 5 [148]
Rat aorta In vitro Substance P 63 [149]
Brain
Rat medial prefrontal cortex In vivo Cocaine 8 [150]
Rat somatosensory cortex In vivo Electrical stimulation 126–190 [151]
Rat auditory cortex In vitro Electrical stimulation 0.38 [152]
Rat cerebellum In vitro Electrical stimulation 2.2 [153]
Rat cerebellum In vitro Electrical stimulation 4 [154]
Rat striatum In vivo Electrical stimulation 2.5 [155]
Rat striatum In vivo Electrical stimulation 3 [156]
Rat striatum In vivo Electrical stimulation 4.5 [28]
Rat striatum In vivo Electrical stimulation 8 [27]
Guinea pig laterodorsal tegmental nucleus In vitro Electrical stimulation 33 [157]
Mouse olfactory bulb In vitro Electrical stimulation 100 [158]
In vivo Odorant 18–84
Rat cortex In vivo Impact injury 83 [159]
Rat cortex In vivo Ischaemia 1000 [14]
Rat cortex In vivo Ischaemia 17 [13]
Cat nucleus tractus solitarius In vivo L-Arginine 3 [30]
Rat cerebellum In vitro NMDA 1800 [160]
Cat ventrolateral medulla In vivo NMDA 1.1 [29]
Rat cerebral cortex In vivo NMDA 20 [161]
Rat striatum In vivo NMDA 176 [162]
Rat striatum In vivo NMDA 520 [149]
Rat hippocampus In vitro NMDA 250 [20]
Glutamate 350
Rat hippocampus In vivo NMDA 400 [163]
Heart
Rabbit heart In vitro Basal 1200 [164]
Rat heart In vitro A23187 (Ca2+ ionophore) 650 [147]
Dog coronary sinus In vivo Acetylcholine 7 [165]
Guinea pig heart In vivo Bradykinin 21 [166]
Other
Mouse kidney In vitro Basal 70–200 [167]
Rat kidney In vitro Basal 0.15 [168]
Rat Lung In vivo LPS 140 [147]
Guinea pig trachea In vitro Bradykinin 0.002 [9]
Guinea pig bronchiole In vitro Bradykinin 0.0004 [9]
Guinea pig myenteric ganglion In vitro Nicotine 46 [169]
Guinea pig circular muscle In vitro Nicotine 124 [169]
Rat spinotrapezius muscle In vitro Acetylcholine 300 [170]
94 C.N. Hall, J. Garthwaite / Nitric Oxide 21 (2009) 92–103is 2 million-fold too insensitive (detection limit = 10 nM [31]). A
calibration error is suspected.
With such an immense variability of values reported in the lit-
erature, it is difﬁcult to come to any ﬁrm conclusion. As things
stand, the lower reported values are probably closer to the truth,
signifying that physiological NO may be <10 nM rather than
>100 nM.
Indirect NO indicators
Fluorescent probes
Probes that bind NO with a high degree of selectivity and alter
their ﬂuorescence as a result, offer the highly desirable prospect ofimaging NO concentrations over time and distance in living tissues
in a quantitative manner. The most popular have been diamino
derivatives of ﬂuorescein (DAF-2) and rhodamine (DAR), which
are available as cell permeating acetoxymethyl esters that undergo
hydrolysis intracellularly to liberate the active compound. Such
compounds are typically marketed as NO detectors and are re-
puted to have sensitivity to NO in the low nanomolar range
[32,33]. Strictly speaking, however, they are not NO detectors be-
cause they do not react with NO. Various mechanisms have been
proposed to explain the changes in ﬂuorescence in cells and tis-
sues, an attractive one being that of Wardman [34], who suggested
that non-speciﬁc oxidation of the ﬂuorophore transforms one of
the aromatic amino groups into an NH radical; NO binds to the rad-
ical, leading to the formation of a triazole ring and a change in ﬂuo-
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Fig. 3. NO concentrations calculated to inhibit cytochrome c oxidase by 10% (NO10%
inhibition) or 50% (NOIC50 ) in relation to the O2 concentration.
C.N. Hall, J. Garthwaite / Nitric Oxide 21 (2009) 92–103 95rescence. This mechanism helps explain many experimental obser-
vations of non-speciﬁcity/interference and implies that a change in
ﬂuorescence, even if prevented by NO synthase inhibition or scav-
enging, does not necessarily signify a change in NO concentration.
Simply a change in the redox state of a cell could alter the degree of
oxidation of the ﬂuorophore leading to a change in the amount of
the radical species available to react with NO and, hence, a change
in ﬂuorescence. Interpretation of the ﬂuorescent signals in terms of
NO is therefore problematic and quantifying the signals in terms of
NO concentration is not feasible.
A more recent approach has been to make ﬂuorophores com-
plexed with Cu2+. Binding of NO causes reduction to Cu+, which
dissociates, and the formation of NO+, which nitrosates a nitrogen
atom on the molecule, increasing the ﬂuorescence emission [35–
37]. Where studied, the NO detection limit is reported to be
17 nM after 5 min exposure [36]. Fluorescent responses have been
detected by imaging in various cells, including endothelial cells
and macrophages, but no attempt has yet been made to calibrate
the responses so the prevailing NO concentrations cannot be
deduced.
NO biosensors
By incorporating an ampliﬁcation step, Sato et al. [38,39] have
succeeded in designing a biosensor capable of detecting NO in con-
centrations in the picomolar range. The basis of the sensor is the
physiological NO receptor, NO-activated GC. On each of the two
GC subunits, Sato et al. positioned a ﬂuorescent cGMP detector that
comprised the cGMP binding domain of cGMP-dependent protein
kinase together with yellow and cyan ﬂuorescent proteins, yielding
a FRET signal on cGMP binding. This approach immediately cir-
cumvents problems of cross-reactivity inherent in all the other
methods discussed above because the NO receptor is extremely
selective for NO. The only other known endogenous ligand for
the receptor is carbon monoxide but its afﬁnity and efﬁcacy are
very low compared with NO [40,41] and, accordingly, a concentra-
tion of 100 lM was needed to give a detectable response [38]; this
concentration was a million-fold higher than the detection limit of
the sensor for NO (0.1 nM). When cultured vascular endothelial
cells were transfected with the sensor, the recorded basal intracel-
lular NO concentration was estimated from calibrations with
authentic NO to be 1 nM. Application of mechanical shear stress
or 1 nM bradykinin to evoke eNOS activation caused a transiently
increased FRET signal (not quantiﬁed). The group then generated
a stable cell line expressing the NO biosensor and used it to mon-
itor NO released from cells [39]. The cell line, named Piccell, was
able to detect astonishingly low NO concentrations, the limit being
20 pM. By positioning a Piccell next to an endothelial cell, or an
endothelial cell on top of a Piccell carpet, it was found that stimu-
lation of the endothelial cell by photorelease of ATP transiently
produced up to 100 pM NO in the adjacent Piccell, falling to about
30 pM a distance of 20 lm away (estimated from their Fig. 4E). In a
similar experiment with a Piccell positioned next to a cultured
brain neurone (from the hippocampus), oscillatory NO signals were
recorded. From the evidence presented (e.g., sensitivity to the volt-
age-gated sodium channel blocker, tetrodotoxin), the oscillations
probably originated in circuit-based neuronal activity. Similar to
endothelial cells, the peak NO concentration reaching the Piccell
was about 100 pM.
If correct, these measurements suggest that the physiological
NO concentration generated at the surface of an endothelial cell
is about 10,000-fold lower than was originally reported by Malin-
ski [31]. The results await conﬁrmation, however, and it is not cer-
tain in the case of the neuronal cultures that the NO was derived
from the immediately adjacent cell as, judging from the image
shown in their Fig. 3C, there appears to be a meshwork of neuronalprocesses in the vicinity that may be active simultaneously. The re-
cent engineering of cGMP biosensors with improved kinetics
[42,43] should provide the means for obtaining complementary
information using endogenous GCs as the NO detectors and ampli-
ﬁers, potentially allowing quantiﬁable responses to NO in the low
nM range and below.
Deductions from functional evidence
NO receptor-mediated responses
Knowledge of the kinetics of receptors for signalling molecules
reveals much about the messages they have evolved to detect and
decode. NO-activated GCs, of which there are two known isoforms
in mammals (a1b1 and a2b1), are the only recognized NO recep-
tors and they transduce all the classical actions of NO in relaxing
smooth muscle, inhibiting platelet aggregation, and in modulating
brain function [44,45]. Despite a long gestation, the functioning of
these NO receptors is now becoming understood in quantitative
terms, thanks partly to the establishment of simple methods for
delivering NO in known, constant concentrations [46] which is a
prerequisite for this type of analysis.
A detailed enzyme-linked receptor model for NO-activated GC
that accounts for all its main functional properties reported over
the years has recently been published [47]. Under the usual bio-
chemical assay conditions, puriﬁed GC protein is activated 50%
by 1 nM NO. This value depends on the concentration of substrate
(GTP) and is also affected by ATP so that, under the presumed
physiological intracellular conditions of 100 lM GTP and 1 mM
ATP, the EC50 increases to about 4 nM (Fig. 2A), a value not far be-
low the 10 nM EC50 measured in intact platelets and other cells
[48,49]. Despite the high afﬁnity of the receptors for NO, they ex-
hibit surprisingly dynamic behaviour, allowing switch-on and
switch-off of cGMP synthesis in a sub-second time scale [50],
determined largely by the kinetics of NO binding and unbinding
[47,51]. The mid-value for activation by steady NO concentrations
(10 nM) is the obvious starting point for considering the likely
range of NO concentrations encountered by target cells using this
transduction pathway.
In other signalling systems, receptors are often present in ex-
cess of those required to generate a maximum response. In the aor-
ta, for instance, only 6% of the available a-adrenoreceptors need to
be occupied by noradrenaline to obtain half-maximal contraction
[52]. A similar situation appears to apply to NO receptors because,
using knockouts of each isoform, either exogenous NO (using S-
nitrosoglutathione) or endogenous NO still relaxed aortic smooth
muscle cGMP-dependently despite a loss of 94% of GC activity,
Fig. 4. Predicted steady-state NO concentration proﬁle at a synapse. (A) The NO sources are assumed to be a 7  7 array of NOS molecules, each producing 20 NO molecules/s
(based on the initial rates of NO formation reported by Santolini et al. [114] after correcting for temperature). Each NOS molecule is assumed to be 100 Å (10 nm) in diameter
[171]. Contour lines show NO concentrations of 0.5, 0.75, 1, and 2 nM NO. (B) Contour lines shown in (A) for the position perpendicular to the plane of the synapse (with an
additional line at 0.25 nM NO) are superimposed on an electron micrograph of a typical excitatory synapse (from [115], reprinted with permission from AAAS; panel modiﬁed
from [45]).
96 C.N. Hall, J. Garthwaite / Nitric Oxide 21 (2009) 92–103although the NO donor became less potent than normal [53]. This
result implies that GC protein is normally present in large excess of
that needed to relax aortic smooth muscle maximally, an arrange-
ment that allows NO concentrations in the lower half of the con-
centration–response curve for GC activation to be maximally
effective. In agreement with this scenario, as illustrated in
Fig. 2B, the concentration–response curve for S-nitrosoglutathi-
one-evoked relaxations in normal rat aortae was shifted about
30-fold to the left of the curve describing the rise of cGMP mea-
sured after about the same time interval [54]. Similarly, in rat
platelets, the NO EC50 for stimulation of cGMP-dependent phos-
phorylation of vasodilator-stimulated phosphoprotein was about
20-fold lower than for stimulation of GC activity in the same cells
[48], the maximum effect being seen at 3 nM (Fig. 2A). There have
also been attempts to measure the potency of NO for smooth mus-
cle relaxation directly, yielding EC50 values of 10 nM [55,56] and
5 nM [57,58], although there may have been uncontrolled losses
of NO in these experiments [56]. Using sodium nitroprusside,
which maximally releases one NO per molecule, the EC50 for relax-
ing rat aorta was reported as 6.5 nM, reducing to about 0.8 nM
when NO synthesis was inhibited [59]. For reducing coronary vas-
cular resistance in perfused rat hearts in vitro, the NO EC50 was
1 nM [60]. This is probably the best indication of the active NO con-
centrations needed to increase blood ﬂow since small vascular
relaxations from low NO concentrations produce a disproportion-
ately large increase in ﬂow (ﬂow is proportional to the fourth
power of the radius of the vessel). Collectively, the evidence indi-
cates that the NO concentrations eliciting physiological responses
in vascular smooth muscle and platelets are likely to fall in the
range 100 pM–5 nM.
Tissue cGMP as an index
Attempts have also been made to use tissue cGMP to bioassay
the prevailing NO concentration under resting conditions and after
imposition of some fairly extreme stimuli. In brain, an established
pathway for activation of nNOS is stimulation of NMDA receptors[45]. Maximal stimulation of these receptors in in vitro brain slice
preparations of cerebellum, however, yielded a level of cGMP that
converted to an average NO concentration of only 2–4 nM NO,
based on calibrations made using clamped NO concentrations on
dispersed cell preparations of the same tissue [61,62]. Applying a
similar protocol to slices of striatum following transient simulated
ischaemia gave a peak apparent NO concentration of about 1 nM
[63]. Even with active iNOS expressed in optic nerve or in hippo-
campal slice cultures, the evidence suggested that the global NO
concentration did not rise to more than 1–2 nM [64,65]. Only when
the iNOS-expressing cell population (microglia) in the slice cul-
tures was expanded further (it was already twice the density found
in vivo) did the prevailing NO become saturating for cGMP genera-
tion, signifying a concentration of 10 nM or more [64]. The under-
lying assumption in this approach is that the tissue NO
concentration is fairly uniform, as would be expected theoretically
[66] and as was indicated by cGMP immunocytochemistry under
similar experimental conditions in the cerebellar cortex [67] and
optic nerve [65]. While it cannot be excluded that there existed
subregions with higher-than-average NO concentrations, the re-
sults suggest that even under potentially pathological conditions,
the global NO concentration in brain tissue remains very low, even
in vitro when scavenging of NO by circulating red blood cells is
lacking.
The functioning of axons in the optic nerve in vitro is tonically
inﬂuenced by NO coming from eNOS in the capillary network
and acting to stimulate axonal GC activity [68]. Again, based on
cGMP immunocytochemistry, this source did not just affect the ax-
ons close to endothelial cells but had a pervasive inﬂuence
throughout the nerve, in accordance with predictions for such a
geometric arrangement of sources [69]. Based on the associated le-
vel of cGMP relative to the maximum obtainable (2.5%) and assum-
ing an EC50 of 10 nM for cGMP generation by NO, the tonic eNOS-
derived NO amounts to about 250 pM. A similar number (100 pM)
was arrived at for the tonic NO concentration from eNOS that sus-
tained basal cGMP levels and promoted synaptic plasticity in hip-
pocampal slices [70]. These results provide further evidence that
1 An increase in VO2 on removal of NO of 45% means that the new, uninhibited
respiration rate is 145% of the rate when inhibited by NO. The respiration rate in the
presence of NO is therefore (100/145)100% = 69% of the uninhibited rate, i.e., a 31%
inhibition.
C.N. Hall, J. Garthwaite / Nitric Oxide 21 (2009) 92–103 97cells can transduce endogenous NO concentrations in the
subnanomolar range into meaningful biological responses. In the
case of the optic nerve, the biological response was a persistent
depolarization of the axons apparently mediated through cyclic
nucleotide-sensitive ion channels [68].
If NO concentrations in the 100 pM range are biologically active,
what concentrations are biologically inactive? The detection limit
for transduction of NO signals through the cGMP pathway in cells
will depend not only on the amount of GC protein but also on the
prevailing phosphodiesterase activity. Estimates of these parame-
ters are available for cerebellar astrocytes and rat platelets [49],
from which it can be calculated that NO concentrations of 10 and
30 pM, respectively, could theoretically generate sufﬁcient cGMP
(200 nM) to engage targets such as cGMP-dependent protein ki-
nases, so an inactive concentration could be as low as 1 pM.
Cytochrome c oxidase as an indicator
Cytochrome c oxidase is inhibited by NO and, as this enzyme is
rate-limiting during oxidative phosphorylation, the degree of inhi-
bition of O2 consumption that occurs in response to NO has been
used to characterise the kinetics of inhibition. Experiments have
demonstrated that respiration of various isolated cell types can
be inhibited by both exogenously and endogenously generated
NO [71–74]. This approach does not, in itself, inform on the phys-
iological NO concentration found in tissues, as dispersed cells have
necessarily lost the physiological ratio of NO-producing (e.g., endo-
thelial cells [74]) and NO-consuming cells (e.g., red blood cells,
brain cells [75,76]). Theoretically, however, the degree of inhibition
of cytochrome c oxidase by NO could be used to estimate the con-
centration of NO in tissues.
NO inhibition of cytochrome c oxidase has both competitive and
uncompetitive components with respect to O2, and is further com-
plicated by the oxidation of NO to nitrite by the enzyme [77]. Sev-
eral studies have modelled these kinetics in detail [78–80], but it
seems that a simple model of purely competitive inhibition is suf-
ﬁcient to account for NO inhibition of O2 consumption at the high
electron ﬂuxes that reﬂect actively respiring tissue [79–81]. Eq. (1)
therefore represents the relationship between NO and O2 concen-
trations and the rate of O2 consumption (VO2 ; as a fraction of the
maximum rate), where KO2 is 0.2–0.22 lM [79,80] and KNO is
0.2–0.25 nM [79,80].
VO2 ¼
O2
O2 þ KO2 1þ NOKNO
  ð1Þ
Eq. (1) can be used to calculate both the NO concentration that
gives half-maximal inhibition (NOIC50 ; Eq. (2)) within the physio-
logical O2 range (20–150 lM [82,83]; Fig. 3) and that when O2 con-
sumption that is 10% inhibited (NO10% inhibition; Eq. (3)).
NOIC50 ¼
KNOðO2 þ KO2 Þ
KO2
ð2Þ
NO10%inhibition ¼ KNOðO2 þ KO2 Þ9KO2
ð3Þ
From these equations, using a mid-range value for KO2
(0.21 lM) and KNO (0.225 nM), 2–16 nM NO would inhibit respira-
tion by 10%, while 22–150 nM NO would give half-maximal inhibi-
tion when O2 is in the physiological range (Fig. 3). The NO
concentration producing any other change in O2 consumption at
a given concentration of O2 could be also calculated from Eq. (1).
Experimental data are inconclusive as to the degree of NO-med-
iated inhibition of respiration that occurs physiologically. In brain
slices, in which the O2 concentration was 0–120 lM, there was no
effect of eNOS or nNOS inhibition on basal O2 consumption or on
O2 consumption following stimulation of these NO synthases,and the NO concentration was estimated to be below 6–22 nM
[84]. This result is consistent with in vivo data, in which NOS inhi-
bition had no effect on cerebral O2 consumption or on the redox
state of cytochrome c oxidase [85–87], and with estimates based
on the prevailing level of cGMP in the brain slices (see above). Re-
sults in muscle and kidney have been more varied than those in
brain. In vivo, some studies ﬁnd no change in O2 consumption after
NOS inhibition (myocardium and skeletal muscle [83,88,89]),
while others report substantial increases (45–55% in skeletal mus-
cle [90,91], indicating that NO inhibits respiration by 30–35%).1 In
vitro, bradykinin-stimulated NO production inhibited O2 consump-
tion by 40% in skeletal muscle slices exposed to 150–240 lM O2
[91] and by 30% in myocardial segments exposed to 140–220 lM
O2 [92]. Similarly, O2 consumption by kidney in vivo was increased
by 90% after NOS inhibition (indicating that NO had been inhibiting
respiration by 53%), while in vitro, NO production from application of
bradykinin led to a 10–15% decrease in O2 consumption in kidney
slices exposed to 200 lM O2 [93]. If competitive inhibition of cyto-
chrome c oxidase by NO were wholly responsible for these effects,
from Eq. (1), the minimum NO concentration in vivo would be 10–
25 nM (using an estimated tissue capillary O2 concentration of
20 lM [94]). In vitro, the minimum required NO concentrations
would be 100, 60 and 23 nM in skeletal muscle, myocardium and
kidney, respectively, if calculated using the lower value of the ap-
plied O2 concentration in each case. Average tissue slice O2, however,
must be lower than in the bathing solution because the tissue con-
sumes O2, so NO concentrations lower than the values given above
would be needed to account for the observed effects. While a direct
action of NO on cytochrome c oxidase is the simplest explanation for
the observations, NO can also decrease respiration via production of
cGMP [91,92], making it difﬁcult to extrapolate the physiological NO
concentration from the degree of respiratory inhibition alone. The
lack of inhibition of respiration in brain, however, sets an upper limit
of 22 nM [84]. Most of the experiments on other tissues, further-
more, would only allow an estimate of the average NO concentration
across the tissue, unless more speciﬁc information was available
about the O2 and VO2 at different depths within it. To get estimates
of local NO levels, direct detection of NO would be required or the
simple competitive model used here would have to be extended to
incorporate the diffusional spread of NO and O2 [84].
Theoretical analyses
Mathematical models have often been used to try to predict the
NO proﬁles generated in the vasculature, brain, lung and other tis-
sues. These studies simulate the diffusion and reaction of NO in
biologically relevant geometries, for example by representing an
arteriole and surrounding layers of endothelium, smooth muscle
and parenchymal tissue as a series of concentric cylinders. Param-
eters for the rate of production, diffusion and consumption of NO in
different cell types are then estimated from experimental data,
allowing the spread of NO from its source (e.g., endothelial cells)
to its targets (e.g., smooth muscle cells) to be calculated.
Many of these studies have generated interesting predictions as
to the spatial and temporal nature of endogenously produced NO
signals. For example, Philippides et al. [95] demonstrated that a
plexus of very ﬁne nerve ﬁbres, such as the NOS-expressing pro-
cesses found in mammalian cerebral cortex, are optimal for gener-
ating a volume NO signal that is tightly linked in space and time to
the region of neuronal activity, a situation of possible relevance to
NO-dependent learning [96]. Models of arteriolar NO production
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reduction in smooth muscle NO levels when free haemoglobin es-
capes from erythrocytes, providing a graphic explanation for the
hypertension seen after haemolytic diseases or after use of haemo-
globin-based oxygen carriers [97,98]. Some models have also
incorporated O2 diffusion and reaction, considering the O2 depen-
dence of NO synthesis and some forms of NO consumption, and
the potential inhibition of O2 consumption by NO [99,100]. Other
models, however, suggest that while NO levels are sensitive to
the amount of O2, they do not reach high enough concentrations
to affect O2 consumption [84].
There is a great deal of variation in the levels of endogenous
NO predicted by these models, ranging from 60 pM to 1 lM in a
single active neuron [66,76], and from 0.1 to 300 nM in arteri-
olar smooth muscle [101,102]. The reason for these wide dispar-
ities is largely due to the choice of values for one critical
parameter: the NO synthesis rate. In the absence of direct infor-
mation, the majority of models [66,69,95,100,103–107] chose an
NO synthesis rate that achieved NO concentrations reported by
Malinski, namely 1 lM NO on the surface of a single stimulated
endothelial cell [31] and a gradient of 0.45 lM NO between the
endothelial and smooth muscle layers of rabbit aorta [108]. Cor-
respondingly, these studies estimate that endogenous NO con-
centrations are in the same range, decreasing to 100–300 nM
in the presence of NO consumption by blood. While these con-
centrations agreed with an early tentative estimate of the po-
tency of NO for activation of GC, (EC50 < 250 nM; [109]), as
discussed above, experiments using stable concentrations of NO
have demonstrated that the sensitivity range of for cellular cGMP
production and vessel relaxation is actually much lower
(EC50  10 nM; [47,56]). The large discrepancy between predic-
tion and experimental evidence on the NO concentrations that
are functionally active has caused some consternation as to
how vessels can avoid being maximally dilated in basal condi-
tions [110]. As discussed above, however, the porphyrinic sensor
developed by Malinski reacts with a number of biological species
and appears to overestimate endogenous NO concentrations by
2–3 orders of magnitude.
Other models have used measurements of NOS activity, rather
than the NO concentration, to calculate the endogenous NO pro-
duction rate. These models predict much lower endogenous levels
of NO. Hall and Garthwaite [76] used the rate of NOS activity mea-
sured in homogenised cerebellum [111] and predicted endogenous
NO concentrations of <10 nM if NO production was activated
throughout the tissue, or 10–30 pM if a single neurone was acti-
vated. Chen and Popel [101,112] used the kinetic models of NO
production from eNOS and nNOS formulated by the Stuehr group
[113,114] together with estimates of the cellular concentrations
of the two NOS proteins. They predicted that NO levels in vascular
smooth muscle would be up to 100 pM if eNOS alone were active
and 4 nM at physiological O2 levels (100 lM) if perivascular nerves
were also synthesizing NO.
For central synapses, an alternative approach is depicted in
Fig. 4. nNOS in synapses is frequently physically associated with
NMDA receptors and is activated when NMDA receptor channels
open, allowing an inﬂux of Ca2+. Each NMDA receptor can only
associate with one nNOS molecule and a typical postsynaptic
membrane may contain up to 50 NMDA receptors [115] and, there-
fore, may have associated with it a similar number of nNOS mole-
cules. Taking the nNOS molecules to exist in a 7  7 array and the
extreme case of all of them being simultaneously active, and gen-
erating NO at the highest rate achievable from measurements of
the activity of puriﬁed nNOS after adjusting for temperature
(20 s1, [114]), the steady-state proﬁle predicts an NO concentra-
tion of only 1 nM just the other side of the synapse (60 nm away
from the central source where the NO concentration is highest),falling to 250 pM within a distance of 1 lm (Fig. 4B). Even within
the source itself (assumed to be a sphere of diameter = 10 nm),
the NO concentration reaches only 2.5 nM. Unless the activity of
nNOS is radically underestimated, it is difﬁcult to understand
how NO concentrations higher than these could exist physiologi-
cally during normal synaptic transmission or when NMDA recep-
tors become activated more persistently, as occurs during
prolonged high-frequency synaptic stimulation. Indeed, as re-
ported by Salerno [116], following persistent activation, nNOS is
predicted to generate NO in a biphasic manner, with a peak activity
after 50 ms followed by a 3- to 4-fold decrease to a steady-state
level, further emphasizing that the NO concentration proﬁles
shown in Fig. 4 are likely to be upper limits.
Because the estimates of NO production used in this and in the
analyses of Chen and Popel [101,112] do not derive directly from
physiological conditions, they are unlikely to be completely accu-
rate, but they have the advantage of making no prior assumptions
about the NO concentration that ought to be produced. The result-
ing predictions concerning endogenous NO concentrations are
within range of the NO concentrations measured with some elec-
trode designs and fall within the sensitivity range for GC activation.NO concentrations in vivo versus in vitro
Many experiments are carried out in vitro, on cultured or dis-
persed cells or tissue slices on the assumption that the properties
of NO signals reasonably reﬂect the in vivo situation. The size
and shape of NO signals are determined by the balance between
the rates of NO synthesis, consumption and diffusion, but in vitro
experiments are often performed under conditions in which the
rates of synthesis and consumption are substantially different from
those existing in vivo, limiting the degree to which we can infer
physiological NO levels from those measured in vitro. Even the
NO diffusion coefﬁcient, which most studies have taken as the va-
lue in aqueous solution, 3300 lm2/s [108], has been measured to
be 4-fold lower in tissues [117], leading to a reduced diffusional
spread of NO from its source and, hence, a higher local NO
concentration.
NO production
The rate of NO synthesis, as discussed above, is related to the
O2 concentration, which ranges from 20 lM in brain [82] to
150 lM in arterial blood [83]. eNOS and nNOS have very differ-
ent O2-dependencies (apparent Km values = 4 lM and 350 lM,
respectively [8]), so the rate of NO production from nNOS is sen-
sitive to the O2 concentration within the physiological range,
while eNOS is not. iNOS has an intermediate O2 dependence
(apparent Km = 130 lM [8]). Importantly, however, in vitro exper-
iments are usually conducted using solutions at air-equilibrated
O2 levels (210 lM O2), or even gassed with 95–100% O2 (1 mM
O2). In cell monolayers at 210 lM O2, the rate of NO production
from nNOS and iNOS will be about 10-fold and 5-fold higher,
respectively, than at a physiological O2 concentration within
parenchymal cells of, say, 20 lM. In tissue slices, the situation is
more complex, as O2 consumption by the tissue generates an O2
gradient across the slice, such that the edge of the slice experi-
ences supraphysiological O2 levels, while the centre may be norm-
oxic or even hypoxic [84]. This means that the rate of NO
production from nNOS and iNOS will differ across the thickness
of the tissue slice, the average rate differing with the bathing O2
concentration and the rate of O2 consumption by the tissue. As
physiological O2 levels are well above the apparent Km of eNOS
for O2, in vitro rates of NO production from eNOS should better re-
ﬂect the in vivo production rates.
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Several pathways have been proposed to participate in con-
sumption of NO. The reaction of NO with oxyhaemoglobin to form
methaemoglobin and nitrate is very fast and, although this reaction
is slowed in blood by the encapsulation of haemoglobin in erythro-
cytes, the rate constant for NO in blood is 350–6500 s1 [75,102],
yielding a luminal half-life of 0.1–2 ms. In vitro preparations do
not have circulating red blood cells and the absence of this power-
ful sink for NO will increase the size and duration of in vitro NO
concentration proﬁles compared to in vivo, particularly, of course,
in blood vessels themselves where most of the NO synthesised is
inactivated by erythrocyte haemoglobin [103]. For parenchymal
cells, the main blood supply is in the capillaries, which typically
represent about 2% of the tissue volume [118]. For NO derived from
capillary endothelial cells, reaction with erythrocyte haemoglobin
has been calculated to give rise to an inactivation rate constant
of 10–20 s1 [69]. For NO generated in the parenchyma, the corre-
sponding rate is calculated to be about 1 s1 when the geometry of
the capillary circulation is taken into consideration and assuming
that any NO entering a capillary is lost (Wood and Garthwaite,
unpublished result).
The extent to which the lack of inactivation by circulating
erythrocytes in in vitro preparations will affect the NO concentra-
tion will depend on the activity of other NO consumption path-
ways. Tissue slices of a brain region (cerebellum) consumed NO
with an apparent maximal rate of 0.2–2 lM/s and a Km of 10 nM
[76,84], meaning that 10 nM NO would decay with a rate constant
of 12–120 s1, equivalent to a half-life of 6–60 ms. The NO inacti-
vation rate in optic nerve appeared to be similarly high [65]. Hepa-
tocytes consumed NO via a process that depended linearly on both
O2 and NO, such that the parenchymal half-life of NO would be
0.09–2 s, depending on the O2 concentration [99]. The identities
of the enzymes responsible for these processes are not yet clear,
but cytochrome P450 oxidoreductase is implicated in at least a
component of NO consumption by brain and a cancer cell line
[119,120], and a similar mechanism seems to be present in endo-
thelial cells [121]. Other enzymes reported to consume NO include
lipoxygenases and prostaglandin H synthase [122,123], cyto-
chrome c oxidase [124], myoglobin [125], and cytoglobin [126].
Further characterisation of the processes that are most relevant
for physiological NO inactivation in different tissues is required
to assess how NO consumption will differ in vitro and in vivo, but
the O2 dependence of the hepatocyte pathway would suggest that
NO consumption is faster in the hyperoxic conditions commonly
used in vitro. Where nNOS is the source of NO, this increase in
NO consumption would not greatly affect the resulting NO concen-
tration, as the rate of NO production would also be increased,
whereas if NO was generated from eNOS, which is not O2 depen-
dent above 20 lM, the NO concentration achieved would fall.
Not all cells are equipped with a mechanism for rapidly con-
suming NO. It may be no coincidence that cells of the cardiovascu-
lar system other than erythrocytes appear deﬁcient. This applies to
platelets and mixed white cells isolated from rat blood [127] as
well as to intact rat aorta [117], although cultured endothelial cells
were found to inactivate NO [121]. Hence, measurements of the
potency of exogenous NO for relaxing aorta (EC50 = 1–10 nM; see
above) may be underestimated but not to the extent that occurs
in other tissues, such as liver or brain. Here, NO consumption gives
rise to substantial NO concentration gradients across the tissue
when it is applied in the bathing medium [76], such that high
NO concentrations must be used in order to achieve low levels of
NO at the centre of the tissue block. In intact brain slices [76]
and optic nerve [65], for example, the apparent EC50 of NO for
cGMP accumulation at steady-state is about 1000-fold higher than
when NO has direct access to its target cells in isolation. Thus, theEC50 for NO measured in such tissues reﬂects the properties of the
inactivation mechanism rather than the sensitivity of the constitu-
ent cells to NO, much as when glutamate and other transmitters
that are subject to avid removal from the extracellular space are
administered in the bathing medium [128]. One disadvantageous
experimental consequence is that when sufﬁcient NO is given to
stimulate GC in the centre of a block of tissue, the applied NO
may be vastly supraphysiological at the edges of the tissue, where
it could have pathological effects, such as respiratory inhibition. In
brain slices, for example, when 1 lM NO was applied to 400 lm
thick brain slices bathed in 1 mM O2, only half of the maximum
possible cGMP was generated [76]. This result indicates that NO
was submaximal for stimulation of GC at the centre of the slice
(<20 nM) but, at its surface, NO would inhibit mitochondrial respi-
ration by 50%.
Conversely, if cell monolayers are used as the experimental
material, a loss of NO inactivation could lead artifactually to the
accumulation of toxic levels of NO. For example, if NO were gener-
ated continuously in a three-dimensional tissue at a global rate of
10 lM/min, the resulting steady-state NO concentration would be
1–2 nM if NO were consumed at the rate estimated for intact brain
tissue [76]. With the same cells dispersed in monolayers at a dilu-
tion of 1:100 (i.e., at approximately 1 mg protein/ml, now generat-
ing 100 nM NO/min) with NO being consumed only through
autoxidation (in an air-equilibrated medium), the resulting NO
concentration would be near 1 lM, which is expected to inhibit
respiration by more than 80%.
Chemical NO consumption
In addition to enzymatic NO metabolism, NO can react rapidly
with other radicals such as superoxide (O2), thiyl radicals (RS)
and lipid peroxyls (LOO) [129–131]. The concentrations of these
radicals are unlikely to be high enough normally in vivo to contrib-
ute signiﬁcantly to NO consumption in physiological conditions.
Superoxide is normally efﬁciently scavenged by superoxide dismu-
tase [132], but its reaction with NO is more likely to occur when it
is produced in larger amounts, for example on reperfusion after
ischaemia or during inﬂammation [133]. Lipid peroxyls are in-
creased in aged animals and in diseases such as atherosclerosis
and neurodegeneration [134]. In addition, their formation in-
creases on tissue disruption [134] and so they can artifactually
generate a sink for NO in vitro [127]. Thiyl radicals, which react
with NO to produce nitrosothiols (RSNO) [135], are produced dur-
ing oxidative stress and after reaction of DNA, peroxyl and tyrosyl
radicals with glutathione (GSH) [136]. In a macrophage cell line
expressing iNOS, however, only a small proportion of endoge-
nously produced NO ended up as nitrosothiol (0.02% [137]), indi-
cating that this reaction is unlikely to contribute much to NO
consumption. It could, however, be artiﬁcially exacerbated
in vitro, as Fe3+ and Cu2+, which are common contaminants of
experimental buffer and salt solutions [138], cause increased thiyl
radical formation [136].Concluding remarks
Leaving aside the incongruous ﬁndings made using many elec-
trode designs, theory and experiment are converging to indicate
that NO operates physiologically at concentrations that are orders
of magnitude lower than the near-micromolar once considered
correct. From the evidence, a range of 100 pM–5 nM appears a rea-
sonable one to settle on although, in principle, NO down in the low
pM range could elicit biological responses in cells through GC acti-
vation. If the range is correct, much of the chemical and biological
reactivity of NO seen at higher NO concentrations becomes of
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examination of conditions suspected to show a build-up of higher
NO concentrations, including inﬂammation and excitotoxic neuro-
degeneration, no such build-up was detected in intact brain tissue.
That higher concentrations can be found under similar conditions
in dispersed cell models may be attributed to an artiﬁcial loss of
NO consumption in such preparations. Nevertheless, two impor-
tant caveats should be raised. One is that the results of some stud-
ies (but not others) on some peripheral organs (but not brain) are
consistent with NO existing in vivo at concentrations capable of
inhibiting mitochondrial respiration signiﬁcantly. Whether the
inhibition is a purely direct effect of NO (necessitating NO concen-
trations in excess of 5 nM) or includes an indirect, possibly cGMP-
mediated, component needs clariﬁcation. The other uncertainty
concerns the NO concentrations existing within a concentrate of
NO-generating cells, for example macrophages or microglia
expressing iNOS in inﬂammatory foci. As indicated by in vitro re-
sults, NO could rise to greater than 10 nM in such a scenario
although whether it does or not in vivowhere the O2 concentration
is lower (reducing the rate of NO synthesis) and where there is tis-
sue perfusion (allowing NO consumption by the blood), remains to
be studied, as does the relevance of such NO concentrations to hu-
mans, in which iNOS-expressing cells appear to produce much less
NO than their rodent counterparts [139,140]. The establishment of
trustworthy methods for direct microelectrode measurement of
NO concentrations, and the (more foreseeable) progression of the
newly developed NO biosensors for quantitative imaging of NO sig-
nalling in subcellular dimensions and in real time to tissues in vivo,
will facilitate advance in this fundamental, but still unsettled, area.
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